Results 51 to 60 of about 65,249 (309)
Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature [PDF]
, 2020 In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is
Aly, Besma +9 more
core
Why human connection is the true metric of research success
FEBS Open Bio, EarlyView.Human‐centred mentorship can be shaped by mentor attributes, actions, intrinsic drive and career ambition. Drawing on reflections across Singapore and France, as well as workshop insights from FEBS‐IUBMB ENABLE 2024, this article shows that human‐centred mentorship creates the conditions for sustainable growth, well‐being and retention in research ...
Timothy Lin Yun Tan +3 more
wiley +1 more source
Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences
Frontiers in Medicine, 2020 The pandemic caused by the new coronavirus (SARS-Cov-2) has encouraged numerous in vitro studies and clinical trials around the world, with research groups testing existing drugs, novel drug candidates and vaccines that can prevent or treat infection ...
Amélia Carolina Lopes Fernandes +8 more
doaj +1 more source
Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa [PDF]
, 2015 The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies.
Andrews +9 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak +4 more
wiley +1 more source
Voices in Bioethics, 2015 Earlier this month, Johnson & Johnson (J&J) announced that it will create an independent panel to review compassionate use requests and determine how the company should respond.[i] This announcement, which comes after high-profile social media campaigns ...
Pranav Aurora
doaj +1 more source
Frontiers in Oncology, 2023 The mitogen-activated protein kinase (MAPK) pathway signaling pathway is one of the most commonly mutated pathways in human cancers. In particular, BRAF alterations result in constitutive activation of the rapidly accelerating fibrosarcoma–extracellular ...
Sarah M. Trinder +45 more
doaj +1 more source
Compassionate Use Programs or Phase IV Trials of Innovative Molecular Targeted Drugs in Lung Cancer: Deal or No Deal? [PDF]
Journal of Thoracic Oncology, 2010 PHASE IV OPEN-LABELED STUDY WITH ERLOTINIB IN SOUTH-EAST ASIANS WITH NON-SMALL CELL LUNG CANCER In this month’s issue of the journal, we are faced with yet another large compassionate use program (expanded access program [EAP/phase IV trial]) with a molecular targeted drug in patients with non-small cell lung cancer (NSCLC).1 This time, Mok et al.1 ...
openaire +1 more source
Arthritis Care &Research, EarlyView.Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg +20 more
wiley +1 more source
Applying real-world data from expanded-access (“compassionate use”) patients to drug development
Journal of Clinical and Translational Science, 2023 Our drug development process has produced many life-saving medications, but patients experiencing rare diseases and similar conditions often are left with limited options for treatment.
June S. Wasser, David J. Greenblatt
doaj +1 more source